Businesses in high drug use areas as potential sources of naloxone during overdose emergencies.
Businesses
Harm reduction
Naloxone
Overdose
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
received:
16
11
2021
revised:
09
02
2022
accepted:
12
02
2022
pubmed:
9
3
2022
medline:
26
4
2022
entrez:
8
3
2022
Statut:
ppublish
Résumé
Naloxone distribution remains a cornerstone of a public health approach to combating the ongoing opioid overdose crisis. Most distribution programs focus on providing naloxone to individuals who use drugs or those closely associated with them (e.g., family). Utilizing businesses as fixed location sources of naloxone could be a valuable supplemental strategy to preventing fatal overdoses that is underexplored in the literature. We surveyed business owners and employees (N = 149) located in neighborhoods characterized by high rates of drug use in Baltimore City. Participants reported their interactions with people who use drugs as well as if they had heard of naloxone, if the business had naloxone on the premises, and how many employees were trained to use naloxone. Most participants reported seeing individuals under the influence of drugs (93%), public drug use (80%), and overdose (66%) while at work. 66% of participants had heard of naloxone. Among those who had heard of naloxone, only 39% reported that there was a naloxone kit in the business and 28% of businesses had multiple employees trained to use naloxone. Businesses are underutilized as potential reliable sources of naloxone. While study participants reported high levels of exposure to drug use and overdose in and around their businesses, their ability to intervene was limited. Efforts to train employees to respond to overdoses and to keep naloxone on site are warranted to supplement existing naloxone distribution efforts and can help empower business staff to help prevent overdose mortality in their communities.
Identifiants
pubmed: 35259680
pii: S0376-8716(22)00094-1
doi: 10.1016/j.drugalcdep.2022.109357
pmc: PMC8957648
mid: NIHMS1786647
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Narcotic Antagonists
0
Naloxone
36B82AMQ7N
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109357Subventions
Organisme : NIAID NIH HHS
ID : P30 AI094189
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA007292
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Références
J Addict Med. 2014 May-Jun;8(3):153-63
pubmed: 24874759
West J Emerg Med. 2018 Nov;19(6):1036-1042
pubmed: 30429939
Drug Alcohol Depend. 2017 Sep 1;178:176-187
pubmed: 28654870
Int J Drug Policy. 2021 Oct;96:103298
pubmed: 34078563
Am J Public Health. 2015 Aug;105(8):1530-7
pubmed: 26066921
Int J Drug Policy. 2015 Dec;26(12):1183-8
pubmed: 26508033
Addiction. 2016 Jul;111(7):1177-87
pubmed: 27028542
Drug Alcohol Depend. 2021 Aug 1;225:108759
pubmed: 34058540
JMIR Form Res. 2020 Dec 23;4(12):e22411
pubmed: 33355094
Int J Drug Policy. 2018 Sep;59:94-97
pubmed: 30075401
Acad Emerg Med. 2019 Feb;26(2):160-173
pubmed: 30074673
BMJ. 2013 Jan 30;346:f174
pubmed: 23372174
Am J Public Health. 2018 Dec;108(12):1649-1651
pubmed: 30403513
Drug Alcohol Depend. 2019 Nov 1;204:107536
pubmed: 31494440
J Subst Abuse Treat. 2018 Nov;94:29-34
pubmed: 30243414
Lancet Public Health. 2018 May;3(5):e218-e225
pubmed: 29678561
N C Med J. 2018 May-Jun;79(3):149-155
pubmed: 29735615
BMC Public Health. 2021 Mar 26;21(1):597
pubmed: 33771150